Compound Detail
CHEMBL515564
TENOFOVIR EXALIDEX 🧪 Phase II
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
🧪 Phase II
Basic Information
| ChEMBL ID | CHEMBL515564 |
| Name | TENOFOVIR EXALIDEX |
| Phase | Phase II |
| Structure Type | MOL |
| InChI Key | SCTJKHUUZLXJIP-RUZDIDTESA-N |
4
Targets
98
Activities
2
Assay Types
26
PK Parameters
19
Publications
5
Known Names
2
Indications
2
Mechanisms
Molecular Properties
569.7
MW (Da)
6.86
ALogP
9
HBA
2
HBD
134.6
PSA (Ų)
0.10
QED
2
Ro5 Violations
25
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| Chirality | Single Enantiomer |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Human immunodeficiency virus type 1 reverse transcriptase inhibitor | INHIBITOR | Human immunodeficiency virus type 1 reverse transcriptase | ✓ | ✓ |
| Reverse transcriptase inhibitor | INHIBITOR | Reverse transcriptase | ✓ | ✓ |
Indications
Communicable Diseases Kidney Diseases
Activity Summary
EC50 92 meas. best 9.18
IC50 6 meas. best 8.74
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| Human immunodeficiency virus 1 CHEMBL378 | EC50 | 9.18 | 8.4887 | 0.7 | 87 |
| Gag-Pol polyprotein CHEMBL3638360 | IC50 | 8.74 | 8.29 | 1.8 | 6 |
| Human immunodeficiency virus 2 CHEMBL380 | EC50 | 8.46 | 8.46 | 3.5 | 3 |
| Hepatitis B virus CHEMBL613497 | EC50 | 6.31 | 6.055 | 490.0 | 2 |
Pharmacokinetic Data
| Parameter | Value | Units | Species |
|---|---|---|---|
| AUC | 441.7 | ng.hr.mL-1 | Rattus norvegicus |
| AUC | 435.2 | ng.hr.mL-1 | Rattus norvegicus |
| AUC | 1832.8 | ng.hr.mL-1 | Rattus norvegicus |
| AUC | 1543.9 | ng.hr.mL-1 | Rattus norvegicus |
| AUC | 5408.0 | ng.hr.mL-1 | Rattus norvegicus |
| AUC | 8406.3 | ng.hr.mL-1 | Rattus norvegicus |
| AUC | - | - | Rattus norvegicus |
| AUC | - | - | Rattus norvegicus |
| AUC | - | - | Rattus norvegicus |
| AUC | - | - | Rattus norvegicus |
| AUC | 5429.8 | ng.hr.mL-1 | Rattus norvegicus |
| AUC | 8050.6 | ng.hr.mL-1 | Rattus norvegicus |
| Cmax | 148.93 | nM | Rattus norvegicus |
| Cmax | 194.65 | nM | Rattus norvegicus |
| Cmax | 665.23 | nM | Rattus norvegicus |
| Cmax | 355.43 | nM | Rattus norvegicus |
| Cmax | 1588.47 | nM | Rattus norvegicus |
| Cmax | 1203.2 | nM | Rattus norvegicus |
| T1/2 | 2.5 | hr | Rattus norvegicus |
| T1/2 | 1.6 | hr | Rattus norvegicus |
| Tmax | 0.5 | hr | Rattus norvegicus |
| Tmax | 0.5 | hr | Rattus norvegicus |
| Tmax | 2.0 | hr | Rattus norvegicus |
| Tmax | 1.0 | hr | Rattus norvegicus |
| Tmax | 2.0 | hr | Rattus norvegicus |
| Tmax | 2.0 | hr | Rattus norvegicus |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
| PubMed | DOI | Target Context | # Activities |
|---|---|---|---|
| 20439609 | 10.1128/aac.00068-10 | Human immunodeficiency virus 1 | 115 |
| 17646420 | 10.1128/aac.00460-07 | Rattus norvegicus | 42 |
| 20439609 | 10.1128/aac.00068-10 | PBMC | 26 |
| 20439609 | 10.1128/aac.00068-10 | ADMET | 6 |
| 17646420 | 10.1128/aac.00460-07 | Unchecked | 4 |
| 20439609 | 10.1128/aac.00068-10 | Human immunodeficiency virus 2 | 3 |
| - | 10.6019/CHEMBL4651402 | SARS-CoV-2 | 2 |
| 17646420 | 10.1128/aac.00460-07 | Hepatitis B virus | 2 |
| 17646420 | 10.1128/aac.00460-07 | Human immunodeficiency virus 1 | 2 |
| 17646420 | 10.1128/aac.00460-07 | PBMC | 1 |
| 17646420 | 10.1128/aac.00460-07 | MT2 | 1 |
| 17646420 | 10.1128/aac.00460-07 | HepG2 | 1 |
| 20439609 | 10.1128/aac.00068-10 | HeLa | 1 |
| 20439609 | 10.1128/aac.00068-10 | CEM-SS | 1 |
| 20439609 | 10.1128/aac.00068-10 | HepG2 | 1 |
| 27405794 | 10.1021/acs.jmedchem.6b00428 | Human immunodeficiency virus 1 | 1 |
| 27405794 | 10.1021/acs.jmedchem.6b00428 | PBMC | 1 |
| 27405794 | 10.1021/acs.jmedchem.6b00428 | ADMET | 1 |
| 17646420 | 10.1128/aac.00460-07 | ADMET | 1 |
Data from ChEMBL 36 via Core Engine